SLI381

08/01/2002 - "The primary objective of this study was to assess the efficacy and safety of SLI381 compared with placebo in the treatment of attention-deficit/hyperactivity disorder (ADHD) in children in a naturalistic school and home setting. "
01/01/2012 - "Adderall XR is commonly prescribed for children and adolescents with attention deficit/hyperactivity disorder. "
11/01/2004 - "Adderall XR is indicated for the treatment of attention deficit hyperactivity disorder in children and adolescents, with recent US Food and Drug Administration approval for attention deficit hyperactivity disorder in adults. "
06/01/2003 - "SLI381 appears to be a useful treatment option for many children with ADHD."
11/01/2001 - "SLI381: a long-acting psychostimulant preparation for the treatment of attention-deficit hyperactivity disorder."

11/01/2004 - "Potentially important benefits of Adderall XR are proven safety and efficacy in adults with attention deficit hyperactivity disorder and positive postmarketing findings in treating oppositional defiant disorder -- the most common comorbidity in children with attention deficit hyperactivity disorder. "
03/01/2006 - "Efficacy and safety of mixed amphetamine salts extended release (adderall XR) in the management of oppositional defiant disorder with or without comorbid attention-deficit/hyperactivity disorder in school-aged children and adolescents: A 4-week, multicenter, randomized, double-blind, parallel-group, placebo-controlled, forced-dose-escalation study."

04/01/2012 - "Not acute myocardial infarction in a teenager due to Adderall XR."
01/01/2012 - "We present a case of a 15-year-old male who suffered a myocardial infarction after starting Adderall XR. "
01/01/2012 - "Acute myocardial infarction in a teenager due to Adderall XR."
09/01/2009 - "Re: Myocardial infarction associated with Adderall XR and alcohol use in a young man."
03/01/2009 - "Myocardial infarction associated with adderall XR and alcohol use in a young man."

05/01/2007 - "Adderall XR (Shire BioChem Inc, Canada), a medication used to treat attention deficit hyperactivity disorder, was withdrawn from the Canadian market in February 2005 due to concerns of possible cardiotoxicity and cerebral vascular events among a small number of individuals who had taken the medication. "

12/01/2023 - "Posterior Reversible Encephalopathy Syndrome With Visual Disturbances in an Adolescent After Overdose With Adderall XR: A Case Report."